Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 2
1984 2
1986 2
1989 1
1991 1
1992 1
1994 1
2010 2
2011 2
2012 1
2013 1
2014 2
2015 1
2016 1
2017 5
2018 1
2019 1
2020 3
2021 1
2022 2
2023 0
Text availability
Article attribute
Article type
Publication date

Search Results

27 results
Results by year
Filters applied: . Clear all
Page 1
Probiotic peanut oral immunotherapy versus oral immunotherapy and placebo in children with peanut allergy in Australia (PPOIT-003): a multicentre, randomised, phase 2b trial.
Loke P, Orsini F, Lozinsky AC, Gold M, O'Sullivan MD, Quinn P, Lloyd M, Ashley SE, Pitkin S, Axelrad C, Metcalfe JR, Su EL, Tey D, Robinson MN, Allen KJ, Prescott SL, Galvin AD, Tang MLK; PPOIT-003 study group. Loke P, et al. Among authors: axelrad c. Lancet Child Adolesc Health. 2022 Mar;6(3):171-184. doi: 10.1016/S2352-4642(22)00006-2. Epub 2022 Feb 4. Lancet Child Adolesc Health. 2022. PMID: 35123664 Clinical Trial.
Cohort Profile: Melbourne Atopy Cohort study (MACS).
Lowe AJ, Lodge CJ, Allen KJ, Abramson MJ, Matheson MC, Thomas PS, Barton CA, Bennett CM, Erbas B, Svanes C, Wjst M, Gómez Real F, Perret JL, Russell MA, Southey MC, Hopper JL, Gurrin LC, Axelrad CJ, Hill DJ, Dharmage SC. Lowe AJ, et al. Among authors: axelrad cj. Int J Epidemiol. 2017 Feb 1;46(1):25-26. doi: 10.1093/ije/dyw011. Int J Epidemiol. 2017. PMID: 27097746 No abstract available.
Probiotic peanut oral immunotherapy is associated with long-term persistence of 8-week sustained unresponsiveness and long-lasting quality-of-life improvement.
Loke P, Hsiao KC, Lozinsky AC, Ashley SE, Lloyd M, Pitkin S, Axelrad CJ, Jayawardana KS, Tey D, Su EL, Robinson M, Leung ASY, Dunn Galvin A, Tang MLK. Loke P, et al. Among authors: axelrad cj. Clin Exp Allergy. 2022 Jun;52(6):806-811. doi: 10.1111/cea.14137. Epub 2022 May 10. Clin Exp Allergy. 2022. PMID: 35485166 No abstract available.
Human milk oligosaccharide profiles and allergic disease up to 18 years.
Lodge CJ, Lowe AJ, Milanzi E, Bowatte G, Abramson MJ, Tsimiklis H, Axelrad C, Robertson B, Darling AE, Svanes C, Wjst M, Dharmage SC, Bode L. Lodge CJ, et al. Among authors: axelrad c. J Allergy Clin Immunol. 2021 Mar;147(3):1041-1048. doi: 10.1016/j.jaci.2020.06.027. Epub 2020 Jul 7. J Allergy Clin Immunol. 2021. PMID: 32650022
Probiotics and oral immunotherapy for peanut allergy - Authors' reply.
Tang MLK, Hsiao KC, Ponsonby AL, Donath S, Orsini F, Axelrad C, Pitkin S. Tang MLK, et al. Among authors: axelrad c. Lancet Child Adolesc Health. 2017 Nov;1(3):e1-e2. doi: 10.1016/S2352-4642(17)30101-3. Epub 2017 Oct 10. Lancet Child Adolesc Health. 2017. PMID: 30169172 No abstract available.
Childhood wheeze phenotypes show less than expected growth in FEV1 across adolescence.
Lodge CJ, Lowe AJ, Allen KJ, Zaloumis S, Gurrin LC, Matheson MC, Axelrad C, Welsh L, Bennett CM, Hopper J, Thomas PS, Hill DJ, Hosking CS, Svanes C, Abramson MJ, Dharmage SC. Lodge CJ, et al. Among authors: axelrad c. Am J Respir Crit Care Med. 2014 Jun 1;189(11):1351-8. doi: 10.1164/rccm.201308-1487OC. Am J Respir Crit Care Med. 2014. PMID: 24796409
Early-life risk factors for childhood wheeze phenotypes in a high-risk birth cohort.
Lodge CJ, Zaloumis S, Lowe AJ, Gurrin LC, Matheson MC, Axelrad C, Bennett CM, Hill DJ, Hosking CS, Svanes C, Abramson MJ, Allen KJ, Dharmage SC. Lodge CJ, et al. Among authors: axelrad c. J Pediatr. 2014 Feb;164(2):289-94.e1-2. doi: 10.1016/j.jpeds.2013.09.056. Epub 2013 Nov 14. J Pediatr. 2014. PMID: 24238860 Clinical Trial.
A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study.
Lowe AJ, Su JC, Allen KJ, Abramson MJ, Cranswick N, Robertson CF, Forster D, Varigos G, Hamilton S, Kennedy R, Axelrad C, Tang MLK, Dharmage SC. Lowe AJ, et al. Among authors: axelrad c. Br J Dermatol. 2018 Jan;178(1):e19-e21. doi: 10.1111/bjd.15747. Epub 2017 Dec 1. Br J Dermatol. 2018. PMID: 28639306 Clinical Trial. No abstract available.
27 results